### 广州7月19日电
记者蔡敏婕报道：
在今天举行的新闻发布会上，优时比公司宣布，其自主研发的生物制剂比奇珠单抗（商品名：倍捷乐）获得国家药品监督管理局（NMPA）的批准，正式上市。这一批准标志着比奇珠单抗成为治疗活动性强直性脊柱炎（AS，放射学阳性中轴型脊柱关节炎）成人患者的全新选择，为患者带来了希望。
强直性脊柱炎是一种慢性炎症性疾病，主要影响脊柱和骨盆区域的关节，导致疼痛、僵硬和功能受限。随着病情进展，可能影响其他关节和身体系统。比奇珠单抗的获批，为常规治疗效果不佳或患者无法耐受现有治疗方案的患者提供了新的治疗手段。
比奇珠单抗通过抑制特定免疫细胞的功能，减轻炎症反应，从而改善强直性脊柱炎患者的症状。其独特的作用机制和临床研究结果，显示了在控制疾病活动性、减少炎症和提高患者生活质量方面的潜力。
优时比公司表示，将与医疗机构、患者组织紧密合作，确保比奇珠单抗的合理应用和患者能够获得及时的治疗。同时，公司也将继续进行深入研究，探索比奇珠单抗在其他炎症性疾病的治疗潜力。
### 结语：
比奇珠单抗的上市，不仅为强直性脊柱炎患者带来了新的治疗选择，也体现了生物技术在治疗复杂炎症性疾病方面的重要进展。未来，随着更多创新药物的问世，强直性脊柱炎患者的治疗将更加多样化，生活质量有望得到显著提升。
英语如下：
### “Beceodarimab Approved for Treating Ankylosing Spondylitis”
Keywords: Beceodarimab, Ankylosing Spondylitis, Market Approval
### Guangzhou, July 19th
By Cai Minjie:
In a press conference held today, UCB, the company, announced that its自主研发 biologic Beceodarimab (trade name: Bixalium) has received approval from the National Medical Products Administration (NMPA) for its market launch. This approval signifies a new treatment option for adult patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis), offering hope to patients.
Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the joints of the spine and pelvis, causing pain, stiffness, and functional limitations. As the disease progresses, it may affect other joints and body systems. The approval of Beceodarimab provides a new treatment option for patients who have not responded well to conventional treatments or cannot tolerate existing treatment regimens.
Beceodarimab works by inhibiting the function of specific immune cells, reducing inflammation, and thus improving the symptoms of ankylosing spondylitis patients. Its unique mechanism of action and clinical trial results suggest potential in controlling disease activity, reducing inflammation, and enhancing patient quality of life.
UCB stated that it will work closely with healthcare institutions and patient organizations to ensure the appropriate use of Beceodarimab and ensure that patients can receive timely treatment. The company will also continue its research to explore the potential of Beceodarimab in treating other inflammatory diseases.
### Conclusion:
The approval of Beceodarimab not only offers new treatment options for patients with ankylosing spondylitis but also highlights significant progress in biotechnology for treating complex inflammatory diseases. As more innovative drugs emerge in the future, the treatment options for ankylosing spondylitis patients will become more diversified, with the potential for a significant improvement in their quality of life.
【来源】http://www.chinanews.com/life/2024/07-19/10254260.shtml
Views: 0